Anti-tumor mechanisms of valproate: A novel role for an old drug

Medicinal Research Reviews

Volumn 22, Issue 5, 2002, Pages 492-511

  Blaheta, Roman A ^a   Cinatl Jr , Jindrich ^a,b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Signaling cascade; Tumor differentiation; Tumor growth; Valproic acid

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN KINASE C; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; DNA BINDING; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; REVIEW; SIGNAL TRANSDUCTION; TOXICITY TESTING; TUMOR CELL CULTURE; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; HUMANS; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VALPROIC ACID;

EID: 0036721055     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10017     Document Type: Review

References (186)

1. On the propyl derivatives and decomposition products of ethylacetoacetate
2. Mechanism of anticonvulsant action of valproate
3. Approach to a theory on the activity of the di-n-propylacetic structure
4. Valproic acid and spina bifida
5. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin
6. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase
7. Effects of anticonvulsants on cell growth and enzymatic and receptor binding activity in a neuroblastoma x glioma hybrid cell culture
8. Differentiation therapy of human cancer: Basic science and clinical applications
9. 5,6-Trans-16-ene-vitamin D3: A new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells
10. Induction of terminal differentiation and apoptosis in human colonic carcinoma cells by brefeldin A, a drug affecting ganglioside biosynthesis
11. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
12. Differentiation and metastasis in melanoma
13. Retinoids in neuroblastoma therapy: Distinct biological properties of 9-cis- and all-transretinoic acid
14. Retinoids in breast cancer prevention and treatment. A review of the literature
15. Prostate cancer prevention strategies using antiproliferative or differentiating agents
16. Differentiating agents and nontoxic therapies
17. Targeted therapies for the myeloid leukaemias
18. Induction of differentiation and apoptosis: A possible strategy in the treatment of adult acute myelogenous leukemia
19. Valproic acid for the treatment of pediatric malignant glioma
20. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action
21. Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrate
22. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth
23. Inhibitors of histone deacetylase as new anticancer agents
24. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
25. Reduction of steady-state valproate levels by other antiepileptic drugs
26. Pharmacokinetics of valproic acid in patients with bipolar disorder
27. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells
28. Sodium valproate inhibits in vivo growth of human neuroblastoma cells
29. Induction of differentiation in F9 cells and activation of peroxisome proliferator-activated receptor delta by valproic acid and its teratogenic derivatives
30. Prediction of embryotoxic effects of valproic acid-derivatives with molecular in vitro methods
31. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells
32. Protein kinases as mediators of phosphoinositide 3-kinase signaling
33. Contribution of receptor/G protein signaling to cell growth and transformation
34. Increase in AP-1 transcription factor DNA binding activity by valproic acid
35. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells
36. Valproate robustly enhances AP-1 mediated gene expression
37. Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid
38. Valproic acid-induced changes in gene expression during neurulation in a mouse model
39. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos
40. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation
41. Complex functions of AP-1 transcription factors in differentiation and survival of PC12 cells
42. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: Enhancement by combination with interferon-
43. Regulation of Bcl-2 oncoprotein levels with differentiation of human neuroblastoma cells
44. Hyperoxia induces the neuronal differentiated phenotype of PC12 cells via a sustained activity of mitogen-activated protein kinase induced by Bcl-2
45. Neuronal differentiation of PC12 cells as a result of prevention of cell death by bcl-2
46. Failure to express GAP-43 during neurogenesis affects cell cycle regulation and differentiation of neural precursors and stimulates apoptosis of neurons
47. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression
48. Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period
49. Extracellular-regulated kinases and phosphatidylinositol 3-kinase are involved in brain-derived neurotrophic factor-mediated survival and neuritogenesis of the neuroblastoma cell line SH-SY5Y
50. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation
51. Cell growth control by G protein-coupled receptors: From signal transduction to signal integration
52. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells
53. Transport of valproate and its effects on GABA uptake in astroglial primary culture
54. 3H]valproic acid into lipids in GT1-7 neurons
55. Upregulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway
56. Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways
57. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo
58. Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro
59. Cytotoxicity induced by the combination of valproic acid and tumor necrosis factor-alpha: Implication for valproic acid-associated hepatotoxicity syndrome
60. Sodium valproate downregulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: A property of protein kinase C-mediated mood stabilizers
61. Soybean saponins inhibit cell proliferation by suppressing PKC activation and induce differentiation of HT-29 human colon adenocarcinoma cells
62. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts
63. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts
64. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement
65. Protein kinase C as a drug target: Implications for drug or diet prevention and treatment of cancer
66. Critical targets of protein kinase C in differentiation of tumour cells
67. Multiple biological responses activated by nuclear protein kinase C
68. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB
69. 2+ pathways
70. Molecular control of neural crest formation, migration and differentiation
71. Linking colorectal cancer to Wnt signaling
72. Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors
73. Sodium butyrate-induced differentiation of human LIM2537 colon cancer cells decreases GSK-3beta activity and increases levels of both membrane-bound and Apc/axin/GSK-3beta complex-associated pools of beta-catenin
74. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3
75. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen
76. Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator
77. The peroxisome proliferator-activated receptors: Ligands and activators
78. Peroxisome proliferator-activated receptor agonists
79. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
80. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor
81. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
82. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer
83. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors
84. New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: Activation of the peroxisomal proliferator-activated receptor (PPARdelta)
85. Peroxisome proliferator-activated receptor delta is a specific sensor for teratogenic valproic acid derivatives
86. Peroxisome proliferator-activated receptor-gamma: From adipogenesis to carcinogenesis
87. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans
88. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
89. The multiple roles of PTEN in tumor suppression
90. PTEN a unique tumor suppressor gene
91. The molecular effects of oncogenesis on cell-extracellular matrix adhesion
92. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
93. Histone acetylation and chromatin assembly: A single escort, multiple dances?
94. What's up and down with histone deacetylation and transcription?
95. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
96. beta-estradiol stimulation of DNA synthesis requires different PKC isoforms in HepG2 and MCF7 cells
97. Differential responses of human neuroblastoma and glioblastoma to apoptosis
98. 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent caco-2 cell differentiation
99. Induction of neurite outgrowth by MAP kinase in PC12 cells
100. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)
101. Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells
102. Omega 3 but not omega 6 fatty acids inhibit AP-1 activity and transformation in JB6 cells
103. PPARalpha and GR differentially downregulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells
104. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
105. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
106. Effect of fatty acid supplementation on growth and differentiation of human IMR-32 neuroblastoma cells in vitro
107. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice
108. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: Binding and activation by an aromatic fatty acid with clinical antitumor activity
109. Activation of a human per-oxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs
110. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate
111. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein
112. Neuronal differentiation of neuro 2a cells by inhibitors of cell cycle progression, trichostatin A and butyrolactone I
113. Histone deacetylase inhibitors as potential anti-skin cancer agents
114. Carboxypeptidase A3 (CPA3): A novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells
115. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation
116. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects
117. β-catenin signaling and cancer
118. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro
119. Cell type- and promoter-dependent modulation of the Wnt signaling pathway by sodium butyrate
120. Studies on the teratogen pharmacophore of valproic acid analogues: Evidence of interactions at a hydrophobic centre
121. The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): Asymmetric synthesis and highly stereoselective teratogenicity in mice
122. Accumulation and washout kinetics of valproic acid and its active metabolites
123. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe
124. Transfection of glioma cells with the neural-cell adhesion molecule NCAM: Effect on glioma-cell invasion and growth in vivo
125. Overexpression of a trans-membrane isoform of neural cell adhesion molecule alters the invasiveness of rat CNS-1 glioma
126. Correlation of expression of NCAM and GD3 ganglioside to motile behaviour in neoplastic glia
127. Identification of mood stabilizer-regulated genes by differential-display PCR
128. Induction of neutrophilic differentiation of human promyelocytic leukemic cells by branched-chain carboxylic acid anticonvulsant drugs
129. The anticonvulsant sodium valproate specifically induces the expression of a rat glial heat shock protein which is identified as the collagen type IV receptor
130. In vitro screening for anticonvulsant-induced teratogenesis: Drug alteration of cell adhesivity
131. Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues
132. Effect of antiepileptic drugs on growth of murine lymphoid tumor cells in single-cell culture
133. Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells
134. Valproic acid, but not its non-teratogenic analogue 2-isopropyl-pentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line NTera-2
135. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro
136. Valproic acid, trichostatin and their combination with hemin preferentially enhance g-globin gene expression in human erythroid liquid cultures
137. Activated transcription of the human neuropeptide Y gene in differentiating SH-SY5Y neuroblastoma cells is dependent on transcription factors AP-1, AP-2alpha, and NGFI
138. Identification of an AP-1-like sequence in the promoter region of calcyclin, a S-100-like gene. Enhancement of binding during retinoic acid-induced neuro-blastoma cell differentiation
139. Activation of the human NPY gene during neuroblastoma cell differentiation: Induced transcriptional activities of AP-1 and AP-2
140. Fos and Jun form cell specific protein complexes at the neuropeptide tyrosine promoter
141. Upregulation of Jun/AP-1 during differentiation of N1E-115 neuroblastoma cells
142. TrkA induces differentiation but not apoptosis in C6-2B glioma cells
143. Bone mineralization and osteoblast differentiation are negatively modulated by integrin alpha(v)beta3
144. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase
145. A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: Modulation of megakaryocytic differentiation of K562 cells
146. Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase
147. Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells
148. Suppression of c-Fos gene transcription with malignant transformation of human bronchial epithelial cells
149. Repression of TNF-alpha-induced E-selectin expression by PPAR activators: Involvement of transcriptional repressor LRF-1/ATF3
150. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators
151. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell inter-action
152. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium
153. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury
154. Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells
155. Differentiation and reversal of malignant changes in colon cancer through PPARgamma
156. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells
157. Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells
158. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells
159. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells
160. Downregulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer
161. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
162. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human pancreatic carcinoma cells
163. PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells
164. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma
165. Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells
166. Peroxisome proliferator-activated receptor gamma ligand-induced growth inhibition of human hepatocellular carcinoma
167. Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines
168. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis
169. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer
170. Growth inhibition of myeloid leukemia cells by troglitazone, a ligand for peroxisome proliferator activated receptor gamma, and retinoids
171. Induction of PPARgamma1 expression in human THP-1 monocytic leukemia cells by 9-cis-retinoic acid is associated with cellular growth suppression
172. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity
173. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase
174. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression
175. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells
176. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin
177. Histone deacetylases: A common molecular target for differentiation treatment of acute myeloid leukemias?
178. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia
179. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells
180. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid
181. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis
182. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A
183. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo
184. Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype
185. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
186. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors